Drug Profile
Recombinant human endostatin adenovirus - Chengdu Shi Endor Biological Engineering Technology
Alternative Names: EDS-01Latest Information Update: 23 Jun 2020
Price :
$50
*
At a glance
- Originator Chengdu Shi Endor Biological Engineering Technology
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Angiogenesis inhibitors; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Head and neck cancer
Most Recent Events
- 18 Apr 2020 GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD plans a phase II trial for Head and neck cancer (Late-stage disease) in China (Intratumoural, Injection) (ChiCTR2000029997)
- 29 Mar 2019 Discontinued - Phase-II for Head and neck cancer (Combination therapy) in China (Intratumoural)